1 week Ago By Defense World Staff
JPMorgan Chase & Co. boosted its stake in Protagonist Therapeutics, Inc. ( NASDAQ:PTGX – Free Report ) by 12.
9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 576,977 shares of the company’s stock after acquiring an additional 65,792 shares during the period. JPMorgan Chase & Co.
owned about 0.97% of Protagonist Therapeutics worth $22,271,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock.
FNY Investment Advisers LLC purchased a new position in Protagonist Therapeutics during the fourth quarter worth about $38,000. KBC Group NV grew its position in Protagonist Therapeutics by 54.4% in the 4th quarter.
KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after purchasing an additional 737 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Protagonist Therapeutics by 10.4% during the fourth quarter.
Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after purchasing an additional 295 shares in the last quarter. Cibc World Markets Corp acquired a new position in shares of Protagonist Therapeutics during the 4th quarter valued at $211,000. Finally, Caprock Group LLC acquired a new position in Protagonist Therapeutics in the fourth quarter worth approximately $224,000.
98.63% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of brokerages have commented on PTGX.
Wedbush restated an “outperform” rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a research note on Friday, March 28th. The Goldman Sachs Group reduced their price target on shares of Protagonist Therapeutics from $43.
00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, February 24th. BTIG Research set a $73.
00 price objective on Protagonist Therapeutics in a report on Monday, March 3rd. BMO Capital Markets increased their price target on Protagonist Therapeutics from $62.00 to $72.
00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, Truist Financial raised their price target on Protagonist Therapeutics from $60.00 to $76.
00 and gave the company a “buy” rating in a research note on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.
com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $62.56. Protagonist Therapeutics Trading Up 2.
2 % PTGX stock opened at $42.57 on Thursday. The business’s 50-day moving average is $43.
88 and its 200 day moving average is $42.81. Protagonist Therapeutics, Inc.
has a 12-month low of $24.22 and a 12-month high of $60.60.
The stock has a market cap of $2.61 billion, a price-to-earnings ratio of 16.00 and a beta of 2.
30. Protagonist Therapeutics ( NASDAQ:PTGX – Get Free Report ) last posted its quarterly earnings results on Friday, February 21st. The company reported $1.
98 EPS for the quarter, topping the consensus estimate of ($0.09) by $2.07.
Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.
The company had revenue of $170.64 million during the quarter, compared to analysts’ expectations of $56.65 million.
As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.
Insider Buying and Selling In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.
36. Following the completion of the transaction, the insider now owns 83,892 shares in the company, valued at approximately $4,676,140.08.
The trade was a 26.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink .
Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.
25, for a total transaction of $217,000.00. Following the transaction, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.
50. This represents a 23.35 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last quarter, insiders sold 64,776 shares of company stock valued at $3,585,010. 5.
40% of the stock is currently owned by corporate insiders. About Protagonist Therapeutics ( Free Report ) Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Further Reading Five stocks we like better than Protagonist Therapeutics How to Calculate Options Profits Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore What Are Dividend Champions? How to Invest in the Champions Are Tariffs Threatening Disney’s Comeback Story? Profitably Trade Stocks at 52-Week Highs Is Alphabet a Generational Buying Opportunity at These Levels? Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc.
( NASDAQ:PTGX – Free Report ). Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
